Further tiotropium + olodaterol FDC data on patient outcomes such as quality of life are due to report later this year SAN DIEGO--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only ...

Ingelheim, Germany, 3rd September, 2012 – New phase II data presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that combining tiotropium with olodaterol ...

MONTREAL — For patients with moderate to severe chronic obstructive pulmonary disease (COPD), the dual bronchodilator combination of tiotropium plus olodaterol improves quality of life better than ...

The fixed-dose combination of tiotropium and olodaterol (trade name: Spiolto Respimat) has been approved since July 2015 for maintenance treatment in adults with chronic obstructive pulmonary disease ...

INGELHEIM, Germany--(BUSINESS WIRE)--For media excluding US/Canada and UK Boehringer Ingelheim announced data which add to the growing body of evidence that show ...

The DYNAGITO trial investigated the effectiveness of dual bronchodilation with fixed-dose tiotropium/olodaterol for reducing exacerbations of COPD. Dual bronchodilation with fixed-dose ...

The fixed-dose combination of tiotropium and olodaterol (trade name: Spiolto Respimat) has been approved since July 2015 for maintenance treatment in adults with chronic obstructive pulmonary disease ...

The US Food and Drug Administration (FDA) last week approved a once-daily oral inhalation spray combining tiotropium and olodaterol (Stiolto Respimat, Boehringer Ingelheim) for chronic obstructive ...

In the PHYSACTO trial, exercise capacity was measured by the length of time people with COPD could walk in an Endurance Shuttle Walking Test, which measures how far someone can walk at a standard ...

asthma inhaler In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS. After ...

Boehringer Ingelheim today announced the first Phase III data for the once-daily fixed-dose combination of tiotropium and olodaterol. Results from the Phase III VIVACITO™ study show that once-daily ...

Chronic obstructive pulmonary disease (COPD) is a progressive disease that makes it hard to breathe. The fixed-dose combination of tiotropium and olodaterol (trade name: Spiolto Respimat) has been ...